Method for the treatment of a scleroderma disease
AssigneeUcb Biopharma Srl
InventorsTimothy Scott JOHNSON, John ATKINSON, Jorg Hans Wilhelm DISTLER, David John ABRAHAM
Life of this patent
Estimating the term…
Abstract
The present invention relates to an anti-transglutaminase type 2 (TG2) antibody for use in the treatment of a scleroderma disease, such as localized or systemic scleroderma.
Claims10
An anti-Transglutaminase type 2 (TG2) antibody for use in the treatment of a subject having a scleroderma disease or in the prevention of the development of a scleroderma disease.
A method for treating a subject having a scleroderma disease or for preventing the development a scleroderma disease in a subject comprising administering a therapeutically effective amount of an anti-TG2 antibody to said subject.
Use of an anti-Transglutaminase type 2 (TG2) antibody for the manufacturing of a medicament in the treatment of a subject having a scleroderma disease or for the prevention of the development of a scleroderma disease in a subject.
Dependencies are inferred from the claim text.